Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.65 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912624 | 0.87 | KEAP1 (0.65) | KEAP1GLO1ALOX15HTTPTGS1 | |
| SCHEMBL29826581 | 0.87 | KEAP1 (0.65) | KEAP1GLO1ALOX15HTTPTGS1 | |
| SCHEMBL21783687 | 0.81 | TNF (0.49) | RORC | |
| SCHEMBL17737617 | 0.80 | RECQL (0.69) | GLO1SLC22A12 | |
| SCHEMBL2124660 | 0.79 | KEAP1 (1.00) | KEAP1GLO1ALOX15HTTJAK2 | |
| SCHEMBL17737476 | 0.77 | ALOX12 (0.62) | GLO1HTT | |
| SCHEMBL27214183 | 0.77 | SLC40A1 (0.66) | GLO1HTTRORC | |
| SCHEMBL17737677 | 0.76 | RECQL (0.58) | GLO1HTTSLC22A12 | |
| SCHEMBL11983469 | 0.75 | TNF (0.46) | ALOX15 | |
| SCHEMBL11509065 | 0.74 | KEAP1 (0.77) | KEAP1GLO1ALOX15HTTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| EP-1831157-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | Pfizer Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067587-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | PFIZER LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264425-A1 | CHEMICAL COMPOUNDS | POLR2E, POLR2A, POLRMT | KEAP1 1335/4885GLO1 1663/4885ALOX15 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.